uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1855 | Q34 | What are the names of the genes that are targeted by the drug Rosuvastatin Calcium in the treatment of atherosclerosis? | In the context of atherosclerosis, the drug Rosuvastatin Calcium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atherosclerosis%" OR LOWER(efo_term) LIKE "%atherosclerosis%") AND (LOWER(drugName) LIKE "%rosuvastatin calcium%" OR LOWER(tradeNames_list) LIKE "%rosuvastatin calcium%" OR LOWER(syns_list) LIKE "%rosuvastatin calcium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104217', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104251', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104183', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104149', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104132', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104234', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104200', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104166', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.925 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of Fever? | In the context of Fever, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fever%" OR LOWER(efo_term) LIKE "%fever%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840155', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840392', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840471', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840550', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840708', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840787', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840866', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841024', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841103', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841182', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841261', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841419', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841498', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841577', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841656', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841735', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840945', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840313', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839997', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839839', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839760', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841340', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840629', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840234', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840076', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839918', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1697 | Q34 | What are the names of the genes that are targeted by the drug Relugolix in the treatment of prostate adenocarcinoma? | In the context of prostate adenocarcinoma, the drug Relugolix targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate adenocarcinoma%" OR LOWER(efo_term) LIKE "%prostate adenocarcinoma%") AND (LOWER(drugName) LIKE "%relugolix%" OR LOWER(tradeNames_list) LIKE "%relugolix%" OR LOWER(syns_list) LIKE "%relugolix%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096986', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096954', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096946', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096970', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096978', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096962', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1656 | Q34 | What are the names of the genes that are targeted by the drug Tenapanor Hydrochloride in the treatment of irritable bowel syndrome? | In the context of irritable bowel syndrome, the drug Tenapanor Hydrochloride targets the gene solute carrier family 9 member A3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%irritable bowel syndrome%" OR LOWER(efo_term) LIKE "%irritable bowel syndrome%") AND (LOWER(drugName) LIKE "%tenapanor hydrochloride%" OR LOWER(tradeNames_list) LIKE "%tenapanor hydrochloride%" OR LOWER(syns_list) LIKE "%tenapanor hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094308', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'syns_list': "['AZD-1722 HYDROCHLORIDE', 'AZD1722', 'AZD1722 hydrochloride', 'RDX-5791RDX5791', 'Tenapanor dihydrochloride', 'Tenapanor hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3'}, {'UUID': 'DrugTargetsIndication121923_text_1094304', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'syns_list': "['AZD-1722 HYDROCHLORIDE', 'AZD1722', 'AZD1722 hydrochloride', 'RDX-5791RDX5791', 'Tenapanor dihydrochloride', 'Tenapanor hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3'}, {'UUID': 'DrugTargetsIndication121923_text_1094316', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'syns_list': "['AZD-1722 HYDROCHLORIDE', 'AZD1722', 'AZD1722 hydrochloride', 'RDX-5791RDX5791', 'Tenapanor dihydrochloride', 'Tenapanor hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3'}, {'UUID': 'DrugTargetsIndication121923_text_1094312', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'syns_list': "['AZD-1722 HYDROCHLORIDE', 'AZD1722', 'AZD1722 hydrochloride', 'RDX-5791RDX5791', 'Tenapanor dihydrochloride', 'Tenapanor hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1606 | Q34 | What are the names of the genes that are targeted by the drug Enalapril Maleate in the treatment of heart failure? | In the context of heart failure, the drug Enalapril Maleate targets the gene angiotensin I converting enzyme. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%enalapril maleate%" OR LOWER(tradeNames_list) LIKE "%enalapril maleate%" OR LOWER(syns_list) LIKE "%enalapril maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091877', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091891', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091893', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091899', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091907', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091909', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091915', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091923', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091925', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091931', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091933', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091941', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091947', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091949', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091955', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091957', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091963', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091965', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091971', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091973', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091979', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091987', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091989', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091995', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091997', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092003', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092011', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092013', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092019', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092021', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092027', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092029', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092035', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092037', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092043', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092045', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092051', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092053', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092059', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092061', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092067', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092069', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092075', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092077', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092083', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092085', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091981', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091917', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091885', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091869', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091861', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091859', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092005', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091939', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091901', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091883', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091875', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091867', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.767 | Q34 | What are the names of the genes that are targeted by the drug Fentanyl in the treatment of neoplasm? | In the context of neoplasm, the drug Fentanyl targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%fentanyl%" OR LOWER(tradeNames_list) LIKE "%fentanyl%" OR LOWER(syns_list) LIKE "%fentanyl%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_786062', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785389', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786327', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785532', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785433', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785598', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785455', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785664', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785910', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785312', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786365', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785323', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785543', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786670', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786632', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785576', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785796', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786783', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785609', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785834', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785631', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785378', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786175', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785675', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786251', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785488', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785948', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786441', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785719', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785986', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785521', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786479', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786024', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786517', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785757', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786745', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785554', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786669', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785356', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786708', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785795', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786707', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785587', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786859', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785444', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786746', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785833', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786822', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785620', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786821', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786784', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785871', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785872', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785653', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786213', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785477', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786176', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786289', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785686', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786099', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785301', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786252', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785947', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785565', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785334', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786593', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785400', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786328', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785985', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786404', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785720', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786403', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786366', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786556', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786023', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786442', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785411', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786555', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786480', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786518', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786061', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786860', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785758', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786138', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786137', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786898', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786897', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786594', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786290', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786214', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786100', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785642', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785466', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785909', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785499', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785345', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786631', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785367', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785510', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785422', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.996 | Q34 | What are the names of the genes that are targeted by the drug Fesoterodine Fumarate in the treatment of overactive bladder? | In the context of overactive bladder, the drug Fesoterodine Fumarate targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%overactive bladder%" OR LOWER(efo_term) LIKE "%overactive bladder%") AND (LOWER(drugName) LIKE "%fesoterodine fumarate%" OR LOWER(tradeNames_list) LIKE "%fesoterodine fumarate%" OR LOWER(syns_list) LIKE "%fesoterodine fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857309', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857318', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857321', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857324', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857330', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857333', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857336', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857342', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857345', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857348', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857351', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857357', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857360', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857363', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857366', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857369', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857372', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857375', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857378', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857381', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857384', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857387', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857339', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857315', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857303', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857297', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857294', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857354', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857327', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857312', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857306', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857300', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.391 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of psoriasis? | In the context of psoriasis, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242234', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242250', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.237 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222197', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222327', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222067', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221937', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221872', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222262', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222132', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222002', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1493 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of non-Hodgkins lymphoma? | In the context of non-Hodgkins lymphoma, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-hodgkins lymphoma%" OR LOWER(efo_term) LIKE "%non-hodgkins lymphoma%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057594', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058077', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058238', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058399', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058721', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058882', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059043', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059365', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059526', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059687', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059848', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060170', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060331', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060492', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060653', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060814', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060975', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061136', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061297', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061458', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061619', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061941', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062102', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062263', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062424', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062585', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062907', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063068', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063229', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063390', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063551', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063712', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063873', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064034', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064195', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064356', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064517', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064678', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064839', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065000', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065161', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065322', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065483', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065644', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065805', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065966', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066127', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066288', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066449', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066610', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066771', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067093', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067254', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067415', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067576', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067737', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067898', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068220', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068381', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068542', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068703', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068864', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069025', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069186', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069347', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069508', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069669', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069830', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069991', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070152', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070313', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070474', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070635', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070796', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070957', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071118', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071279', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071440', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071601', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071762', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071923', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072084', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072245', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072406', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066932', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061780', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059204', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057916', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057272', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056950', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056789', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068059', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062746', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060009', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058560', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057755', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057433', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057111', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.269 | Q34 | What are the names of the genes that are targeted by the drug Loteprednol Etabonate in the treatment of inflammation? | In the context of inflammation, the drug Loteprednol Etabonate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inflammation%" OR LOWER(efo_term) LIKE "%inflammation%") AND (LOWER(drugName) LIKE "%loteprednol etabonate%" OR LOWER(tradeNames_list) LIKE "%loteprednol etabonate%" OR LOWER(syns_list) LIKE "%loteprednol etabonate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225430', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225445', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225446', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225453', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225461', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225462', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225469', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225477', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225478', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225485', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225486', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225494', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225501', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225502', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225509', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225510', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225517', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225518', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225525', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225526', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225533', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225541', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225542', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225549', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225550', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225557', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225565', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225566', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225573', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225574', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225581', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225582', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225589', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225590', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225597', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225598', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225605', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225606', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225534', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225470', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225438', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225422', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225414', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225413', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225558', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225493', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225454', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225437', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225429', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225421', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1238 | Q34 | What are the names of the genes that are targeted by the drug Mirabegron in the treatment of overactive bladder? | In the context of overactive bladder, the drug Mirabegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%overactive bladder%" OR LOWER(efo_term) LIKE "%overactive bladder%") AND (LOWER(drugName) LIKE "%mirabegron%" OR LOWER(tradeNames_list) LIKE "%mirabegron%" OR LOWER(syns_list) LIKE "%mirabegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937775', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937823', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937839', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937855', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937887', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937903', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937919', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937951', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937967', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937983', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937999', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938031', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938047', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938063', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938079', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938095', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938111', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938127', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938143', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938159', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938175', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938207', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938223', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938239', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938255', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938191', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937807', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937743', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937711', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937695', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937935', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938015', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937871', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937791', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937759', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937727', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.119 | Q34 | What are the names of the genes that are targeted by the drug Escitalopram Oxalate in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Escitalopram Oxalate targets the gene solute carrier family 6 member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%escitalopram oxalate%" OR LOWER(tradeNames_list) LIKE "%escitalopram oxalate%" OR LOWER(syns_list) LIKE "%escitalopram oxalate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206550', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206577', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206586', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206595', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206568', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206532', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206514', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206505', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206604', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206559', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206541', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206523', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1822 | Q34 | What are the names of the genes that are targeted by the drug Eteplirsen in the treatment of Duchenne muscular dystrophy? | In the context of Duchenne muscular dystrophy, the drug Eteplirsen targets the gene dystrophin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%duchenne muscular dystrophy%" OR LOWER(efo_term) LIKE "%duchenne muscular dystrophy%") AND (LOWER(drugName) LIKE "%eteplirsen%" OR LOWER(tradeNames_list) LIKE "%eteplirsen%" OR LOWER(syns_list) LIKE "%eteplirsen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100458', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100464', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100466', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100468', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100472', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100474', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100476', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100480', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100482', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100484', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100486', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100490', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100492', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100494', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100496', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100498', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100500', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100502', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100504', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100506', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100478', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100462', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100454', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100450', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100448', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100488', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100470', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100460', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100456', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100452', 'drugName': 'Eteplirsen', 'tradeNames_list': "['Exondys 51']", 'syns_list': "['AVI-4658', 'Eteplirsen']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.678 | Q34 | What are the names of the genes that are targeted by the drug Erdafitinib in the treatment of bladder tumor? | In the context of bladder tumor, the drug Erdafitinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2 and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bladder tumor%" OR LOWER(efo_term) LIKE "%bladder tumor%") AND (LOWER(drugName) LIKE "%erdafitinib%" OR LOWER(tradeNames_list) LIKE "%erdafitinib%" OR LOWER(syns_list) LIKE "%erdafitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707172', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707220', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707236', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707252', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707284', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707300', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707316', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707348', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707364', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707380', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707396', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707428', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707444', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707460', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707476', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707492', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707508', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707524', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707540', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707556', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707572', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707604', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707620', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707636', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707652', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707668', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707700', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707716', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707732', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707748', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707764', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707780', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707796', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707812', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707828', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707844', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707860', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707876', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707892', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707908', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707924', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707940', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707956', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707972', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707988', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708004', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708020', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708036', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708052', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708068', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708084', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708116', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708132', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708148', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708164', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708180', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708196', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708228', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708244', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708260', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708276', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708292', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708308', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708324', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708340', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708356', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708372', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708388', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708404', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708420', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708436', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708452', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708468', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708484', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708500', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708516', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708532', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708548', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708564', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708580', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708596', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708612', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708100', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707588', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707332', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707204', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707140', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707108', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707092', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708212', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707684', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707412', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707268', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707188', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707156', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707124', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.251 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of fungal infectious disease? | In the context of fungal infectious disease, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fungal infectious disease%" OR LOWER(efo_term) LIKE "%fungal infectious disease%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222211', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222341', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222081', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221951', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221886', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222276', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222146', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222016', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1778 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of multiple myeloma? | In the context of multiple myeloma, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple myeloma%" OR LOWER(efo_term) LIKE "%multiple myeloma%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099875', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100040', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100095', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100150', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099985', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099765', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099655', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099600', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100205', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099930', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099820', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099710', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1977 | Q34 | What are the names of the genes that are targeted by the drug Topotecan in the treatment of neoplasm? | In the context of neoplasm, the drug Topotecan targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%topotecan%" OR LOWER(tradeNames_list) LIKE "%topotecan%" OR LOWER(syns_list) LIKE "%topotecan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193661', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193662', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193673', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193574', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193649', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193672', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193575', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193577', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193647', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193646', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193561', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical adenocarcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193564', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193632', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193567', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193638', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193557', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193640', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193628', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193629', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193566', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193670', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193633', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical adenocarcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193568', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193571', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193643', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193639', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193636', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193641', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193660', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193560', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193556', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193659', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193671', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193569', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193609', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193623', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193545', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mediastinal Neoplasms', 'efo_term': 'mediastinal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193614', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193615', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193618', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193546', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193621', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193622', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193656', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193655', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193626', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193537', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193549', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193550', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193617', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mediastinal Neoplasms', 'efo_term': 'mediastinal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193551', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193542', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193654', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193554', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193543', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193667', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193665', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193666', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193528', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'Genital neoplasm, female', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193592', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningeal Neoplasms', 'efo_term': 'meningeal neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193597', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193600', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'Genital neoplasm, female', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193520', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningeal Neoplasms', 'efo_term': 'meningeal neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193525', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193530', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193602', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.96 | Q34 | What are the names of the genes that are targeted by the drug Palonosetron Hydrochloride in the treatment of Chemotherapy-induced nausea and vomiting? | In the context of Chemotherapy-induced nausea and vomiting, the drug Palonosetron Hydrochloride targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chemotherapy-induced nausea and vomiting%" OR LOWER(efo_term) LIKE "%chemotherapy-induced nausea and vomiting%") AND (LOWER(drugName) LIKE "%palonosetron hydrochloride%" OR LOWER(tradeNames_list) LIKE "%palonosetron hydrochloride%" OR LOWER(syns_list) LIKE "%palonosetron hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205524', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205542', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205548', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205554', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205566', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205572', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205578', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205590', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205596', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205602', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205608', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205620', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205626', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205632', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205638', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205644', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205650', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205656', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205662', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205668', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205674', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205686', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205692', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205698', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205704', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205710', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205722', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205728', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205734', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205740', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205680', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205584', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205536', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205512', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205500', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205494', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205716', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205614', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205560', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205530', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205518', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205506', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.34 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole Lauroxil in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Aripiprazole Lauroxil targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%aripiprazole lauroxil%" OR LOWER(tradeNames_list) LIKE "%aripiprazole lauroxil%" OR LOWER(syns_list) LIKE "%aripiprazole lauroxil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158029', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158047', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158053', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158059', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158071', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158077', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158083', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158095', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158101', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158107', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158113', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158125', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158131', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158137', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158143', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158149', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158155', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158161', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158167', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158173', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158179', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158191', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158197', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158203', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158209', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158215', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158227', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158233', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158239', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158245', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158251', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158257', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158263', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158269', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158275', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158281', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158287', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158293', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158299', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158305', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158311', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158317', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158323', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158329', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158335', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158341', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158347', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158353', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158359', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158365', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158371', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158383', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158389', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158395', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158401', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158407', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158413', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158425', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158431', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158437', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158443', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158449', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158455', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158461', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158467', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158473', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158479', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158485', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158491', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158497', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158503', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158509', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158515', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158521', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158527', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158533', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158539', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158545', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158551', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158557', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158563', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158569', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158575', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158581', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158587', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158593', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158377', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158185', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158089', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158041', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158017', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158005', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157999', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158419', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158221', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158119', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158065', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158035', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158023', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158011', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1955 | Q34 | What are the names of the genes that are targeted by the drug Baclofen in the treatment of Spinal cord injury? | In the context of Spinal cord injury, the drug Baclofen targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spinal cord injury%" OR LOWER(efo_term) LIKE "%spinal cord injury%") AND (LOWER(drugName) LIKE "%baclofen%" OR LOWER(tradeNames_list) LIKE "%baclofen%" OR LOWER(syns_list) LIKE "%baclofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193247', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193322', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193347', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193297', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193147', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193122', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193197', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193272', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193222', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193172', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1653 | Q34 | What are the names of the genes that are targeted by the drug Abiraterone Acetate in the treatment of prostate adenocarcinoma? | In the context of prostate adenocarcinoma, the drug Abiraterone Acetate targets the gene cytochrome P450 family 17 subfamily A member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate adenocarcinoma%" OR LOWER(efo_term) LIKE "%prostate adenocarcinoma%") AND (LOWER(drugName) LIKE "%abiraterone acetate%" OR LOWER(tradeNames_list) LIKE "%abiraterone acetate%" OR LOWER(syns_list) LIKE "%abiraterone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094286', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094299', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.452 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of type III hypersensitivity reaction disease? | In the context of type III hypersensitivity reaction disease, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type iii hypersensitivity reaction disease%" OR LOWER(efo_term) LIKE "%type iii hypersensitivity reaction disease%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361099', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361258', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361311', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361364', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361470', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361523', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361576', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361682', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361735', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361788', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361841', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361947', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362000', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362053', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362106', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362159', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362212', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362265', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362318', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362371', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362424', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362530', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362583', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362636', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362689', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362742', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362848', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362901', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362954', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363007', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363060', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363113', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363166', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363219', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363272', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363325', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363378', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363431', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363484', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363537', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363590', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363643', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363696', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363749', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363802', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363855', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363908', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363961', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364014', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364067', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364120', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364226', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364279', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364332', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364385', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364438', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364491', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364597', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364650', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364703', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364756', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364809', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364862', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364915', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364968', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365021', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365074', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365127', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365180', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365233', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365286', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365339', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365392', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365445', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365498', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365551', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365604', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365657', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365710', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365763', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365816', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365869', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365922', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365975', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366028', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366081', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364173', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362477', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361629', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361205', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360993', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360887', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360834', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364544', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362795', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361894', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361417', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361152', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361046', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360940', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.721 | Q34 | What are the names of the genes that are targeted by the drug Encorafenib in the treatment of cancer? | In the context of cancer, the drug Encorafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%encorafenib%" OR LOWER(tradeNames_list) LIKE "%encorafenib%" OR LOWER(syns_list) LIKE "%encorafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752613', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752473', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752319', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752529', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752543', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752235', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752305', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752249', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752459', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752599', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752431', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752501', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752669', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752655', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752641', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752291', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752347', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752277', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752403', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752627', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752333', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752389', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752361', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752571', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752417', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752375', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752515', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752585', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752487', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752445', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752263', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752557', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752287', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752343', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752455', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752665', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752357', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752483', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752301', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752371', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752511', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752525', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752385', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752539', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752553', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752245', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752315', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752399', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752567', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752497', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752581', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752413', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752595', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752609', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752469', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752273', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752427', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752259', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752623', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752637', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752231', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752329', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752651', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752441', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1249 | Q34 | What are the names of the genes that are targeted by the drug Armodafinil in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Armodafinil targets the gene solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%armodafinil%" OR LOWER(tradeNames_list) LIKE "%armodafinil%" OR LOWER(syns_list) LIKE "%armodafinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939099', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939156', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939175', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939194', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939232', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939251', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939270', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939308', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939327', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939346', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939365', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939137', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939061', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939023', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939004', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939289', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939213', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939118', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939080', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939042', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1504 | Q34 | What are the names of the genes that are targeted by the drug Pralatrexate in the treatment of cancer? | In the context of cancer, the drug Pralatrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%pralatrexate%" OR LOWER(tradeNames_list) LIKE "%pralatrexate%" OR LOWER(syns_list) LIKE "%pralatrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072533', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072438', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072495', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072476', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072514', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072457', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072529', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072434', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072453', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072472', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072510', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072491', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072428', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072449', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072468', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072486', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072487', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072524', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072448', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072523', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072466', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072504', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072505', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072485', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072429', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072506', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072430', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072447', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072467', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072525', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1 | Q34 | What are the names of the genes that are targeted by the drug Lonafarnib in the treatment of Hutchinson-Gilford progeria syndrome? | In the context of Hutchinson-Gilford progeria syndrome, the drug Lonafarnib targets the gene farnesyltransferase, CAAX box, alpha and farnesyltransferase, CAAX box, beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hutchinson-gilford progeria syndrome%" OR LOWER(efo_term) LIKE "%hutchinson-gilford progeria syndrome%") AND (LOWER(drugName) LIKE "%lonafarnib%" OR LOWER(tradeNames_list) LIKE "%lonafarnib%" OR LOWER(syns_list) LIKE "%lonafarnib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149003', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta'}, {'UUID': 'DrugTargetsIndication121923_text_149041', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta'}, {'UUID': 'DrugTargetsIndication121923_text_148965', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha'}, {'UUID': 'DrugTargetsIndication121923_text_148927', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha'}, {'UUID': 'DrugTargetsIndication121923_text_148908', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha'}, {'UUID': 'DrugTargetsIndication121923_text_149022', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta'}, {'UUID': 'DrugTargetsIndication121923_text_148984', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta'}, {'UUID': 'DrugTargetsIndication121923_text_148946', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'syns_list': "['Lonafarnib', 'SCH 66336', 'SCH-66336', 'SCH66336', 'Sarasar']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1683 | Q34 | What are the names of the genes that are targeted by the drug Ertugliflozin in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Ertugliflozin targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%ertugliflozin%" OR LOWER(tradeNames_list) LIKE "%ertugliflozin%" OR LOWER(syns_list) LIKE "%ertugliflozin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096239', 'drugName': 'Ertugliflozin', 'tradeNames_list': "['Steglatro']", 'syns_list': "['Ertugliflozin', 'Ertugliflozin l-pyroglutamic acidErtugliflozin pidolate', 'MK-8835', 'PF-04971729', 'PF-04971729-00PF04971729', 'Pf-04971729']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096242', 'drugName': 'Ertugliflozin', 'tradeNames_list': "['Steglatro']", 'syns_list': "['Ertugliflozin', 'Ertugliflozin l-pyroglutamic acidErtugliflozin pidolate', 'MK-8835', 'PF-04971729', 'PF-04971729-00PF04971729', 'Pf-04971729']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1109 | Q34 | What are the names of the genes that are targeted by the drug Tucatinib in the treatment of cancer? | In the context of cancer, the drug Tucatinib targets the gene erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%tucatinib%" OR LOWER(tradeNames_list) LIKE "%tucatinib%" OR LOWER(syns_list) LIKE "%tucatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924534', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924506', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924482', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924454', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924524', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924478', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924450', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924520', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924492', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924510', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924538', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924548', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924468', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924552', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924496', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924464', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924474', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924502', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924503', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924475', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924516', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924517', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924460', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924461', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924488', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924530', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924531', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924447', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924446', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924489', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924544', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924545', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1116 | Q34 | What are the names of the genes that are targeted by the drug Ivosidenib in the treatment of neoplasm? | In the context of neoplasm, the drug Ivosidenib targets the gene isocitrate dehydrogenase (NADP(+)) 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%ivosidenib%" OR LOWER(tradeNames_list) LIKE "%ivosidenib%" OR LOWER(syns_list) LIKE "%ivosidenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924579', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924596', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924597', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924605', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924614', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924615', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924623', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924632', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924633', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924641', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924642', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924651', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924659', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924660', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924668', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924669', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924677', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924678', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924686', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924687', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924695', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924704', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924705', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924713', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924714', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924722', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924731', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924732', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924740', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924741', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924749', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924750', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924758', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924759', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924767', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924768', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924776', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924777', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924785', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924786', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924794', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924795', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924696', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924624', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924588', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924570', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924561', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924560', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924723', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924650', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924606', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924587', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924578', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924569', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.84 | Q34 | What are the names of the genes that are targeted by the drug Apomorphine Hydrochloride in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Apomorphine Hydrochloride targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%apomorphine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%apomorphine hydrochloride%" OR LOWER(syns_list) LIKE "%apomorphine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_204001', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204010', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204013', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204016', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204022', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204025', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204028', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204034', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204037', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204040', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204043', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204049', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204052', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204055', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204058', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204061', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204064', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204067', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204070', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204073', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204076', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204082', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204085', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204088', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204091', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204094', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204100', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204103', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204106', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204109', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204112', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204115', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204118', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204121', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204124', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204127', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204130', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204133', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204136', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204139', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204142', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204145', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204148', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204151', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204154', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204157', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204160', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204163', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204166', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204169', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204172', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204178', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204181', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204184', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204187', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204190', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204193', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204199', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204202', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204205', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204208', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204211', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204214', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204217', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204220', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204223', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204226', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204229', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204232', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204235', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204238', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204241', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204244', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204247', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204250', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204253', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204256', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204259', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204262', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204265', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204268', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204271', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204274', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204277', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204280', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204283', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204175', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204079', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204031', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204007', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_203995', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_203989', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_203986', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204196', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204097', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204046', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204019', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_204004', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_203998', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_203992', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_list': "['Apo-go', 'Apo-go pen', 'Apo-go pfs', 'Apokyn', 'Apomorph hcl', 'BritajectBromophin', 'Dacepton', 'Diagesil', 'Diamorph hcl', 'Diamorph rocheDiamorph,cocaine,chlorpromazine', 'Diaphine', 'Euphorin', 'KynmobiUprima']", 'syns_list': "['Apokinon', 'Apomine', 'Apomorphine HCl', 'Apomorphine hclApomorphine hydrochloride', 'Apomorphine hydrochloride hemihydrateApomorphine hydrochloride hydrate', 'Apomorphinum muriaticumDiamorphine hydrochloride ', 'Ixense', 'Kw-6500', 'NSC-11442', 'NSC-755875Taluvian']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1274 | Q34 | What are the names of the genes that are targeted by the drug Irinotecan Hydrochloride in the treatment of carcinoma? | In the context of carcinoma, the drug Irinotecan Hydrochloride targets the gene DNA topoisomerase I. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%carcinoma%" OR LOWER(efo_term) LIKE "%carcinoma%") AND (LOWER(drugName) LIKE "%irinotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%irinotecan hydrochloride%" OR LOWER(syns_list) LIKE "%irinotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_942599', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941599', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941200', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942300', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940699', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942299', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941000', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942399', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940900', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941700', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942600', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941799', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941299', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941800', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940700', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940899', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942199', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941500', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940999', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941999', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941699', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941099', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942100', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942000', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942499', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942099', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941199', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941400', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941399', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941100', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942200', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941499', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941600', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942400', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941900', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942500', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940799', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941899', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941300', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940800', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941087', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941485', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941489', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940788', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941587', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941588', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941098', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941487', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941488', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941589', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940883', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940794', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941498', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940994', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940887', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940683', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940798', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941494', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941085', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940787', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941089', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941483', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941088', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941598', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941394', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941594', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941094', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941398', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941383', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941385', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940898', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940698', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941294', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941581', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940789', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941298', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940894', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940685', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941287', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940689', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941081', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941285', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940687', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941288', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941389', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940694', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940981', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940889', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940888', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941289', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940688', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941381', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941387', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940885', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940781', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric carcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940783', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941388', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940785', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941583', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941585', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.681 | Q34 | What are the names of the genes that are targeted by the drug Erdafitinib in the treatment of urothelial carcinoma? | In the context of urothelial carcinoma, the drug Erdafitinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2 and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urothelial carcinoma%" OR LOWER(efo_term) LIKE "%urothelial carcinoma%") AND (LOWER(drugName) LIKE "%erdafitinib%" OR LOWER(tradeNames_list) LIKE "%erdafitinib%" OR LOWER(syns_list) LIKE "%erdafitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707128', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707159', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707160', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707175', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707191', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707192', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707207', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707223', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707224', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707239', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707240', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707256', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707271', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707272', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707287', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707288', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707303', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707304', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707319', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707320', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707335', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707351', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707352', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707367', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707368', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707383', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707399', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707400', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707415', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707416', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707431', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707432', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707447', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707448', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707463', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707464', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707479', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707480', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707495', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707496', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707511', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707512', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707527', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707528', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707543', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707544', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707559', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707560', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707575', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707576', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707591', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707607', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707608', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707623', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707624', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707639', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707640', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707656', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707671', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707672', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707687', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707688', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707703', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707704', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707719', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707720', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707735', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707736', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707751', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707752', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707767', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707768', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707783', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707784', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707799', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707800', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707815', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707816', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707831', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707832', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707847', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707848', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707863', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707864', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707879', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707880', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707592', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707336', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707208', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707144', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707112', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707096', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707095', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707655', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707384', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707255', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707176', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707143', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707127', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707111', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1437 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of hyperlipidemia? | In the context of hyperlipidemia, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperlipidemia%" OR LOWER(efo_term) LIKE "%hyperlipidemia%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043742', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043784', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043798', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043812', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043840', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043854', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043868', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043896', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043910', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043924', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043938', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043966', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043980', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043994', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043882', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043770', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043714', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043686', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043672', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043952', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043826', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043756', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043728', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043700', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1053 | Q34 | What are the names of the genes that are targeted by the drug Pemetrexed in the treatment of malignant peritoneal mesothelioma? | In the context of malignant peritoneal mesothelioma, the drug Pemetrexed targets the gene thymidylate synthetase, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase and dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%malignant peritoneal mesothelioma%" OR LOWER(efo_term) LIKE "%malignant peritoneal mesothelioma%") AND (LOWER(drugName) LIKE "%pemetrexed%" OR LOWER(tradeNames_list) LIKE "%pemetrexed%" OR LOWER(syns_list) LIKE "%pemetrexed%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_918796', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918985', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919048', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919111', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919237', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919300', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919363', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918922', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918670', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918544', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918481', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919174', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918859', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918733', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918607', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.775 | Q34 | What are the names of the genes that are targeted by the drug Hydromorphone Hydrochloride in the treatment of pain? | In the context of pain, the drug Hydromorphone Hydrochloride targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%hydromorphone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%hydromorphone hydrochloride%" OR LOWER(syns_list) LIKE "%hydromorphone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_792058', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792076', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792013', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792084', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792039', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792066', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792049', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792057', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792075', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792040', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792004', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792012', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792085', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792067', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792030', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792048', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792021', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792003', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792031', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792022', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792016', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792042', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792043', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792007', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792024', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792051', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792052', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792006', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_791997', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792025', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792015', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792033', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792069', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_791998', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792070', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792034', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792078', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792079', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792060', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792061', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1783 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of osteitis deformans? | In the context of osteitis deformans, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteitis deformans%" OR LOWER(efo_term) LIKE "%osteitis deformans%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099719', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099825', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099829', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099880', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099935', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099939', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099990', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100045', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100049', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100100', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100104', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100159', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100210', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100214', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099994', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099774', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099664', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099609', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099605', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100155', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099884', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099770', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099715', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099660', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1266 | Q34 | What are the names of the genes that are targeted by the drug Hydroxyprogesterone Caproate in the treatment of premature birth? | In the context of premature birth, the drug Hydroxyprogesterone Caproate targets the gene progesterone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%premature birth%" OR LOWER(efo_term) LIKE "%premature birth%") AND (LOWER(drugName) LIKE "%hydroxyprogesterone caproate%" OR LOWER(tradeNames_list) LIKE "%hydroxyprogesterone caproate%" OR LOWER(syns_list) LIKE "%hydroxyprogesterone caproate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940462', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940468', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940470', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940466', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940454', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940452', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940458', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940464', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940460', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940456', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'syns_list': "['17-ohpc', '17.alpha.-caproyloxy-p4', 'Depo-proluton', 'HormofortHydroxyprogesterone', 'Hydroxyprogesterone caproateHydroxyprogesterone hexanoate', 'Hylutin', 'NSC-17592Oxiprogesterone caproate', 'Pharlon', 'Primolut depot', 'Procyte depoProge', 'Syngynon', 'Teralutil']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1566 | Q34 | What are the names of the genes that are targeted by the drug Bosentan in the treatment of idiopathic and/or familial pulmonary arterial hypertension? | In the context of idiopathic and/or familial pulmonary arterial hypertension, the drug Bosentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%idiopathic and/or familial pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%idiopathic and/or familial pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%bosentan%" OR LOWER(tradeNames_list) LIKE "%bosentan%" OR LOWER(syns_list) LIKE "%bosentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084238', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084210', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084294', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084266', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1964 | Q34 | What are the names of the genes that are targeted by the drug Lubiprostone in the treatment of irritable bowel syndrome? | In the context of irritable bowel syndrome, the drug Lubiprostone targets the gene chloride voltage-gated channel 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%irritable bowel syndrome%" OR LOWER(efo_term) LIKE "%irritable bowel syndrome%") AND (LOWER(drugName) LIKE "%lubiprostone%" OR LOWER(tradeNames_list) LIKE "%lubiprostone%" OR LOWER(syns_list) LIKE "%lubiprostone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193411', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193426', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193431', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193436', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193446', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193451', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193456', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193466', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193471', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193461', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193421', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193391', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193386', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193401', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193441', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193416', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193406', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193396', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.407 | Q34 | What are the names of the genes that are targeted by the drug Prednisolone Acetate in the treatment of eye inflammation? | In the context of eye inflammation, the drug Prednisolone Acetate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%prednisolone acetate%" OR LOWER(tradeNames_list) LIKE "%prednisolone acetate%" OR LOWER(syns_list) LIKE "%prednisolone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243761', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243744', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243795', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243778', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1711 | Q34 | What are the names of the genes that are targeted by the drug Triptorelin Pamoate in the treatment of prostate carcinoma? | In the context of prostate carcinoma, the drug Triptorelin Pamoate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate carcinoma%" OR LOWER(efo_term) LIKE "%prostate carcinoma%") AND (LOWER(drugName) LIKE "%triptorelin pamoate%" OR LOWER(tradeNames_list) LIKE "%triptorelin pamoate%" OR LOWER(syns_list) LIKE "%triptorelin pamoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097286', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'syns_list': "['Salvacyl', 'Triptorelin (as embonate)', 'Triptorelin embonateTriptorelin pamoate']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097293', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'syns_list': "['Salvacyl', 'Triptorelin (as embonate)', 'Triptorelin embonateTriptorelin pamoate']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1283 | Q34 | What are the names of the genes that are targeted by the drug Pralsetinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Pralsetinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%pralsetinib%" OR LOWER(tradeNames_list) LIKE "%pralsetinib%" OR LOWER(syns_list) LIKE "%pralsetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944313', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944325', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944329', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944333', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944341', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944345', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944349', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944357', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944361', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944365', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944369', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944321', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944305', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944297', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944293', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944353', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944337', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944317', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944309', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944301', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1325 | Q34 | What are the names of the genes that are targeted by the drug Venetoclax in the treatment of neoplasm? | In the context of neoplasm, the drug Venetoclax targets the gene BCL2 apoptosis regulator. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%venetoclax%" OR LOWER(tradeNames_list) LIKE "%venetoclax%" OR LOWER(syns_list) LIKE "%venetoclax%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_989844', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990263', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990757', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990908', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989768', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_991023', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989693', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989958', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990529', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990072', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990795', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990946', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990985', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989692', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990186', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990604', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990833', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990909', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989730', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990681', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989996', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990339', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990415', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990035', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990605', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990566', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990643', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990871', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989882', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990300', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989959', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990984', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990148', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990947', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989921', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990870', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990187', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990149', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989806', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990832', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990491', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989769', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989920', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990110', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989807', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990225', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990794', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990718', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990680', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990073', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989997', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990301', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990377', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990376', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990453', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990034', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990452', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990719', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990528', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_991022', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990756', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990490', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990414', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990338', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989731', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990224', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990567', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989883', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989845', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990642', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990111', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990262', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990141', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989902', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989685', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989781', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989910', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989913', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990168', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990176', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990179', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990255', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990282', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989723', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989788', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989796', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989933', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989799', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990161', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989940', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989948', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989951', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989674', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989971', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989978', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990275', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989819', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989986', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989989', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989826', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.106 | Q34 | What are the names of the genes that are targeted by the drug Ondansetron in the treatment of post operative nausea and vomiting? | In the context of post operative nausea and vomiting, the drug Ondansetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%post operative nausea and vomiting%" OR LOWER(efo_term) LIKE "%post operative nausea and vomiting%") AND (LOWER(drugName) LIKE "%ondansetron%" OR LOWER(tradeNames_list) LIKE "%ondansetron%" OR LOWER(syns_list) LIKE "%ondansetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205900', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205860', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205980', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205940', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.693 | Q34 | What are the names of the genes that are targeted by the drug Edoxaban Tosylate in the treatment of deep vein thrombosis? | In the context of deep vein thrombosis, the drug Edoxaban Tosylate targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%deep vein thrombosis%" OR LOWER(efo_term) LIKE "%deep vein thrombosis%") AND (LOWER(drugName) LIKE "%edoxaban tosylate%" OR LOWER(tradeNames_list) LIKE "%edoxaban tosylate%" OR LOWER(syns_list) LIKE "%edoxaban tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710336', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710308', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710301', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710322', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710329', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710315', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1574 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of immune system disease? | In the context of immune system disease, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085632', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086037', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086172', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086307', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086577', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086712', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086847', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087117', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087252', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087387', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087522', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087792', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087927', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088062', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088197', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088332', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088467', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088602', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088737', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088872', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089007', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089277', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089412', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089547', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089682', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089817', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090087', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090222', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090357', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090492', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090627', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089142', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086982', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085902', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085362', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085092', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084957', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089952', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087657', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086442', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085767', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085497', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085227', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.832 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of influenza? | In the context of influenza, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%influenza%" OR LOWER(efo_term) LIKE "%influenza%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829264', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829579', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829684', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829789', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829999', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830104', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830209', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830419', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830524', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830629', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830734', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830944', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831049', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831154', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831259', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831364', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831469', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831574', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831679', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831784', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831889', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832099', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832204', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832309', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832414', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832519', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832729', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832834', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831994', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830314', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829474', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829054', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828844', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828739', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832624', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830839', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829894', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829369', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829159', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828949', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.63 | Q34 | What are the names of the genes that are targeted by the drug Metoclopramide Hydrochloride in the treatment of Anorexia? | In the context of Anorexia, the drug Metoclopramide Hydrochloride targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 3A and 5-hydroxytryptamine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anorexia%" OR LOWER(efo_term) LIKE "%anorexia%") AND (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_list) LIKE "%metoclopramide hydrochloride%" OR LOWER(syns_list) LIKE "%metoclopramide hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199701', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199669', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199661', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199685', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199693', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199677', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.858 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of Back pain? | In the context of Back pain, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833957', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833800', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834428', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834899', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835370', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835213', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835527', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833643', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834585', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835056', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835684', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835841', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834114', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835998', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834742', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834271', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834190', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834818', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834975', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834347', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835132', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835289', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835917', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833719', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834504', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835446', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835603', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833876', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833562', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834033', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835760', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834661', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1723 | Q34 | What are the names of the genes that are targeted by the drug Telotristat Etiprate in the treatment of Diarrhea? | In the context of Diarrhea, the drug Telotristat Etiprate targets the gene tryptophan hydroxylase 2 and tryptophan hydroxylase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diarrhea%" OR LOWER(efo_term) LIKE "%diarrhea%") AND (LOWER(drugName) LIKE "%telotristat etiprate%" OR LOWER(tradeNames_list) LIKE "%telotristat etiprate%" OR LOWER(syns_list) LIKE "%telotristat etiprate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097499', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097502', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097503', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097501', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097495', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1097494', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1097497', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1097500', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097498', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1097496', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'syns_list': "['LX1032 HIPPURATE', 'LX1606 HIPPURATE', 'Telotristat ethyl hippurateTelotristat etiprate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.225 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of infection? | In the context of infection, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%infection%" OR LOWER(efo_term) LIKE "%infection%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220892', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220868', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220844', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220832', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220904', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220880', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220856', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.147 | Q34 | What are the names of the genes that are targeted by the drug Desonide in the treatment of atopic eczema? | In the context of atopic eczema, the drug Desonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%desonide%" OR LOWER(tradeNames_list) LIKE "%desonide%" OR LOWER(syns_list) LIKE "%desonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217428', 'drugName': 'Desonide', 'tradeNames_list': "['Desonate', 'Desonide', 'Desowen', 'Tridesilon', 'Verdeso']", 'syns_list': "['D-2083', 'D2083', 'Desonate', 'Desonide', 'NSC-759226']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217431', 'drugName': 'Desonide', 'tradeNames_list': "['Desonate', 'Desonide', 'Desowen', 'Tridesilon', 'Verdeso']", 'syns_list': "['D-2083', 'D2083', 'Desonate', 'Desonide', 'NSC-759226']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217434', 'drugName': 'Desonide', 'tradeNames_list': "['Desonate', 'Desonide', 'Desowen', 'Tridesilon', 'Verdeso']", 'syns_list': "['D-2083', 'D2083', 'Desonate', 'Desonide', 'NSC-759226']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1096 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Undecanoate in the treatment of hypogonadotropic hypogonadism? | In the context of hypogonadotropic hypogonadism, the drug Testosterone Undecanoate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadotropic hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadotropic hypogonadism%") AND (LOWER(drugName) LIKE "%testosterone undecanoate%" OR LOWER(tradeNames_list) LIKE "%testosterone undecanoate%" OR LOWER(syns_list) LIKE "%testosterone undecanoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_922041', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922080', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922093', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922106', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922132', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922145', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922158', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922184', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922197', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922210', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922223', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922249', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922262', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922275', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922288', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922301', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922314', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922327', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922340', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922353', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922366', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922392', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922405', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922418', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922431', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922444', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922470', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922483', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922496', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922379', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922171', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922067', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922015', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921989', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921976', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922457', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922236', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922119', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922054', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922028', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922002', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.375 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of pneumonia? | In the context of pneumonia, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pneumonia%" OR LOWER(efo_term) LIKE "%pneumonia%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218887', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217847', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241142', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218263', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217862', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219318', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241716', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219927', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218278', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219511', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219526', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241552', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219095', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219303', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240814', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240896', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240978', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241224', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219734', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219719', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218486', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241470', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217639', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218070', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241798', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241880', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220774', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218902', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220343', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220150', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220551', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217654', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220566', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241634', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220759', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241060', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218471', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219942', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241388', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218055', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219110', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220358', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218694', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218679', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220135', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241306', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241284', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241448', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241366', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241530', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241612', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241694', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241776', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241858', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240792', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240874', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240956', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241038', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241120', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241202', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219190', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219398', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217526', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218566', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219814', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218774', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220022', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218150', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217734', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220230', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220438', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218982', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217942', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218358', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219606', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1405 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of anthrax infection? | In the context of anthrax infection, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anthrax infection%" OR LOWER(efo_term) LIKE "%anthrax infection%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038219', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038444', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038519', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038594', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038744', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038819', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038894', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039044', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039119', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039194', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039269', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039419', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039494', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039569', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039644', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039719', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039794', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039869', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039944', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040019', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040094', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040244', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040319', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040394', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040469', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040544', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040694', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040769', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040844', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040919', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040994', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041069', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040169', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038969', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038369', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038069', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037919', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037844', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040619', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039344', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038669', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038294', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038144', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037994', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1150 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of follicular thyroid carcinoma? | Trametinib has not been approved by the FDA as a treatment for follicular thyroid carcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%follicular thyroid carcinoma%" OR LOWER(efo_term) LIKE "%follicular thyroid carcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928698', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928818', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928858', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928898', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928978', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929018', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929058', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929138', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929178', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929218', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929258', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929338', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929378', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929418', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929458', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929498', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929538', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929578', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929618', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929658', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929698', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929778', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929818', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929858', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929898', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929938', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930018', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930058', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930098', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930138', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930178', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930218', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930258', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930298', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930338', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930378', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930418', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930458', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930498', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930538', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930578', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930618', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930658', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930698', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930738', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930778', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930818', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930858', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930898', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930938', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930978', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931058', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931098', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931138', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931178', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931218', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931258', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931338', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931378', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931418', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931458', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931498', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931538', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931578', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931618', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931658', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931698', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931738', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931778', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931818', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931858', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931898', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931938', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931978', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932018', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932058', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932098', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932138', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932178', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932218', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932258', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932298', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932338', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932378', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932418', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932458', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931018', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929738', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929098', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928778', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928618', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928538', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928498', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931298', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929978', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929298', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928938', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928738', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928658', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928578', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1888 | Q34 | What are the names of the genes that are targeted by the drug Cinacalcet Hydrochloride in the treatment of secondary hyperparathyroidism? | In the context of secondary hyperparathyroidism, the drug Cinacalcet Hydrochloride targets the gene calcium sensing receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%secondary hyperparathyroidism%" OR LOWER(efo_term) LIKE "%secondary hyperparathyroidism%") AND (LOWER(drugName) LIKE "%cinacalcet hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cinacalcet hydrochloride%" OR LOWER(syns_list) LIKE "%cinacalcet hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149037', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149017', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149012', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149027', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149032', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149022', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1481 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of acute lymphoblastic leukemia? | In the context of acute lymphoblastic leukemia, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute lymphoblastic leukemia%" OR LOWER(efo_term) LIKE "%acute lymphoblastic leukemia%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1063233', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059530', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061929', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060174', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058725', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064022', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059047', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059369', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061285', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059691', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062090', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062573', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060335', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063555', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057115', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063700', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057743', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064183', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056938', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064199', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057904', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057276', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060963', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058065', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061446', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056793', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058226', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062428', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057437', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062251', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058387', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062734', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057099', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062750', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058548', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063877', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057598', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063539', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058709', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063861', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056777', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063716', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058870', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064505', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057759', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064038', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059031', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064360', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057260', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064344', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059192', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057920', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060802', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059353', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061124', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056954', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060979', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061768', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058081', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061301', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059675', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061623', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057421', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061607', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059836', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063072', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058242', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061945', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059997', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062412', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062106', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062267', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060158', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063056', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058403', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062589', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060319', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062911', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057582', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062895', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060480', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064521', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058564', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063378', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060641', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064682', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064666', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063217', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061784', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061140', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060818', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060657', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059208', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059514', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061462', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060013', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063394', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058886', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059852', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060496', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1587 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of subependymal giant cell astrocytoma? | In the context of subependymal giant cell astrocytoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%subependymal giant cell astrocytoma%" OR LOWER(efo_term) LIKE "%subependymal giant cell astrocytoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085645', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086050', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086185', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086320', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086590', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086725', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086860', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087130', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087265', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087400', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087535', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087805', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087940', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088075', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088210', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088345', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088480', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088615', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088750', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088885', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089020', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089290', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089425', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089560', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089695', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089830', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090100', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090235', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090370', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090505', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090640', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089155', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086995', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085915', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085375', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085105', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084970', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089965', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087670', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086455', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085780', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085510', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085240', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1255 | Q34 | What are the names of the genes that are targeted by the drug Alpelisib in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Alpelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%alpelisib%" OR LOWER(tradeNames_list) LIKE "%alpelisib%" OR LOWER(syns_list) LIKE "%alpelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939627', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939690', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939711', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939732', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939669', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939585', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939543', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939522', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939753', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939648', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939606', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939564', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.10 | Q34 | What are the names of the genes that are targeted by the drug Risperidone in the treatment of psychosis? | In the context of psychosis, the drug Risperidone targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_list) LIKE "%risperidone%" OR LOWER(syns_list) LIKE "%risperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149655', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149754', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149787', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149820', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149886', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149919', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149952', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150018', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150051', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150084', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150117', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150183', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150216', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150249', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150282', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150315', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150348', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150381', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150414', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150447', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150480', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150546', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150579', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150612', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150645', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150678', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150744', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150777', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150810', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150843', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150876', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150909', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150942', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150975', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151008', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151041', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151074', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151107', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151140', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151173', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151206', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151239', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150513', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149985', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149721', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149589', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149523', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149490', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150711', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150150', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149853', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149688', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149622', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149556', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.453 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of asthma? | In the context of asthma, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360942', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361047', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361048', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361100', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361153', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361154', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361206', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361259', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361260', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361312', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361313', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361366', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361418', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361419', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361471', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361472', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361524', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361525', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361577', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361578', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361630', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361683', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361684', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361736', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361737', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361789', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361842', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361843', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361895', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361896', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361948', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361949', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362001', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362002', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362054', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362055', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362107', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362108', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362160', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362161', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362213', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362214', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362266', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362267', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362319', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362320', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362372', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362373', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362425', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362426', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362478', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362531', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362532', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362584', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362585', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362637', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362638', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362691', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362743', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362744', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362796', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362797', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362849', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362850', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362902', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362903', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362955', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362956', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363008', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363009', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363061', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363062', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363114', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363115', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363167', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363168', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363220', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363221', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363273', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363274', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363326', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363327', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363379', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363380', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363432', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363433', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362479', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361631', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361207', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360995', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360889', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360836', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360835', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362690', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361790', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361365', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361101', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360994', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360941', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360888', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.713 | Q34 | What are the names of the genes that are targeted by the drug Ponatinib Hydrochloride in the treatment of chronic myelogenous leukemia? | In the context of chronic myelogenous leukemia, the drug Ponatinib Hydrochloride targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase and BCR activator of RhoGEF and GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic myelogenous leukemia%" OR LOWER(efo_term) LIKE "%chronic myelogenous leukemia%") AND (LOWER(drugName) LIKE "%ponatinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%ponatinib hydrochloride%" OR LOWER(syns_list) LIKE "%ponatinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_749871', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749646', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749791', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749686', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749596', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749916', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749616', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749636', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749751', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749656', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749801', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749826', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749696', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749891', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749591', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749896', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749601', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749926', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749611', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749931', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749621', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749631', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749731', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749641', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749761', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749651', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749661', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749821', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749671', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749806', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749681', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749836', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749691', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749841', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749701', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749911', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749711', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749886', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749496', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749906', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749531', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749901', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749481', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749951', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749536', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749921', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749501', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749946', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749541', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749941', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749936', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749546', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749721', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749506', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749741', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749551', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749736', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749781', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749556', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749756', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749511', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749776', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749561', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749771', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749476', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749861', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749566', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749796', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749516', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749816', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749571', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749811', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749491', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749856', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749576', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749831', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749521', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749851', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749581', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749846', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749471', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749956', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749586', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749876', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749526', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749966', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749961', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749866', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749786', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749746', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749726', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749716', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749626', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749486', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749766', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749676', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749881', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749606', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749666', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749706', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_list': "['Iclusig']", 'syns_list': "['AP-24534 HCL', 'AP24534 HCL', 'Ponatinib hydrochloride']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.257 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222217', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222347', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222087', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221957', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221892', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222282', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222152', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222022', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.888 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of cataract? | In the context of cataract, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cataract%" OR LOWER(efo_term) LIKE "%cataract%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837134', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837224', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837254', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837284', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837344', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837374', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837404', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837464', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837494', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837524', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837554', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837614', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837644', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837674', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837704', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837734', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837764', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837794', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837824', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837854', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837884', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837944', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837974', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838004', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838034', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837914', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837194', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837074', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837014', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836984', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837434', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837584', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837314', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837164', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837104', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837044', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.392 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of skin disease? | In the context of skin disease, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242235', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242251', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.914 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of vaginal inflammation? | In the context of vaginal inflammation, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%vaginal inflammation%" OR LOWER(efo_term) LIKE "%vaginal inflammation%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838544', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838667', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838708', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838749', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838831', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838872', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838913', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838995', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839036', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839077', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839118', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839200', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839241', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839282', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839323', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839364', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839405', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839446', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839487', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839528', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839569', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839651', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839692', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839610', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838954', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838626', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838380', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838339', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838462', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839159', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838790', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838585', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838503', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838421', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.931 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840161', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840398', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840477', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840556', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840714', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840793', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840872', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841030', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841109', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841188', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841267', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841425', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841504', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841583', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841662', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841741', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840951', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840319', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840003', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839845', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839766', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841346', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840635', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840240', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840082', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839924', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1689 | Q34 | What are the names of the genes that are targeted by the drug Lesinurad in the treatment of hyperuricemia? | In the context of hyperuricemia, the drug Lesinurad targets the gene solute carrier family 22 member 12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperuricemia%" OR LOWER(efo_term) LIKE "%hyperuricemia%") AND (LOWER(drugName) LIKE "%lesinurad%" OR LOWER(tradeNames_list) LIKE "%lesinurad%" OR LOWER(syns_list) LIKE "%lesinurad%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096803', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096809', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096811', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096813', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096807', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096799', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096795', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096793', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096815', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096805', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096801', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}, {'UUID': 'DrugTargetsIndication121923_text_1096797', 'drugName': 'Lesinurad', 'tradeNames_list': "['Zurampic']", 'syns_list': "['Lesinurad', 'RDEA 594', 'RDEA-594', 'RDEA594']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'SLC22A12', 'approvedName': 'solute carrier family 22 member 12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1219 | Q34 | What are the names of the genes that are targeted by the drug Olodaterol in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Olodaterol targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%olodaterol%" OR LOWER(tradeNames_list) LIKE "%olodaterol%" OR LOWER(syns_list) LIKE "%olodaterol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937157', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937169', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937173', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937177', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937185', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937165', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937149', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937141', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937137', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937181', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937161', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937153', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937145', 'drugName': 'Olodaterol', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744', 'Olodaterol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.464 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol Phosphate in the treatment of hypertension? | In the context of hypertension, the drug Carvedilol Phosphate targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%carvedilol phosphate%" OR LOWER(tradeNames_list) LIKE "%carvedilol phosphate%" OR LOWER(syns_list) LIKE "%carvedilol phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416728', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416740', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416744', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416748', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416756', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416760', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416764', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416772', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416776', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416780', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416784', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416792', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416796', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416800', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416804', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416808', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416812', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416816', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416820', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416824', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416828', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416836', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416840', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416844', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416848', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416852', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416860', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416864', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416868', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416872', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416876', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416880', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416884', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416888', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416892', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416896', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416900', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416904', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416908', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416912', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416916', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416920', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416924', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416928', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416932', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416936', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416940', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416944', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416948', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416952', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416956', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416964', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416968', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416972', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416976', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416980', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416984', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416992', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416996', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417000', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417004', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417008', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417012', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417016', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417020', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417024', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417028', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417032', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417036', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417040', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417044', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417048', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417052', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417056', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417060', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417064', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417068', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417072', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417076', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417080', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417084', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417088', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417092', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417096', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417100', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417104', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416960', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416832', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416768', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416736', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416720', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416712', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416708', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416988', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416856', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416788', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416752', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416732', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416724', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416716', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1254 | Q34 | What are the names of the genes that are targeted by the drug Modafinil in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Modafinil targets the gene solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%modafinil%" OR LOWER(tradeNames_list) LIKE "%modafinil%" OR LOWER(syns_list) LIKE "%modafinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939099', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939156', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939175', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939194', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939232', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939251', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939270', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939308', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939327', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939346', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939365', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939437', 'drugName': 'Modafinil', 'tradeNames_list': "['Modafinil', 'Provigil']", 'syns_list': "['CEP 1538', 'CEP-1538', 'CRC-40476', 'CRL 40476', 'CRL-40476', 'DEP-1538Modafinil', 'Modafinil civ', 'Modaphonil', 'Modiodal', 'NSC-751178NSC-759110', 'THN-102 COMPONENT MODAFINIL', 'THN102 COMPONENT MODAFINIL']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939471', 'drugName': 'Modafinil', 'tradeNames_list': "['Modafinil', 'Provigil']", 'syns_list': "['CEP 1538', 'CEP-1538', 'CRC-40476', 'CRL 40476', 'CRL-40476', 'DEP-1538Modafinil', 'Modafinil civ', 'Modaphonil', 'Modiodal', 'NSC-751178NSC-759110', 'THN-102 COMPONENT MODAFINIL', 'THN102 COMPONENT MODAFINIL']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939505', 'drugName': 'Modafinil', 'tradeNames_list': "['Modafinil', 'Provigil']", 'syns_list': "['CEP 1538', 'CEP-1538', 'CRC-40476', 'CRL 40476', 'CRL-40476', 'DEP-1538Modafinil', 'Modafinil civ', 'Modaphonil', 'Modiodal', 'NSC-751178NSC-759110', 'THN-102 COMPONENT MODAFINIL', 'THN102 COMPONENT MODAFINIL']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939289', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939137', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939061', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939023', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939004', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939403', 'drugName': 'Modafinil', 'tradeNames_list': "['Modafinil', 'Provigil']", 'syns_list': "['CEP 1538', 'CEP-1538', 'CRC-40476', 'CRL 40476', 'CRL-40476', 'DEP-1538Modafinil', 'Modafinil civ', 'Modaphonil', 'Modiodal', 'NSC-751178NSC-759110', 'THN-102 COMPONENT MODAFINIL', 'THN102 COMPONENT MODAFINIL']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939213', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939118', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939080', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939042', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1177 | Q34 | What are the names of the genes that are targeted by the drug Sitagliptin Phosphate in the treatment of stroke? | In the context of stroke, the drug Sitagliptin Phosphate targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%sitagliptin phosphate%" OR LOWER(tradeNames_list) LIKE "%sitagliptin phosphate%" OR LOWER(syns_list) LIKE "%sitagliptin phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933071', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933089', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933095', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933101', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933113', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933119', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933125', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933137', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933143', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933149', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933155', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933167', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933173', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933179', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933185', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933191', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933197', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933203', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933209', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933215', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933221', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933233', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933239', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933245', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933251', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933257', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933269', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933275', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933281', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933287', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933293', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933299', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933305', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933227', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933131', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933083', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933059', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933047', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933041', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933263', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933161', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933107', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933077', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933065', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933053', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.965 | Q34 | What are the names of the genes that are targeted by the drug Baricitinib in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Baricitinib targets the gene Janus kinase 1 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%baricitinib%" OR LOWER(tradeNames_list) LIKE "%baricitinib%" OR LOWER(syns_list) LIKE "%baricitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_843214', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843289', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843314', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843339', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843389', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843414', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843439', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843489', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843514', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843539', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843564', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843614', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843464', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843264', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843164', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843114', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843089', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843589', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843364', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843239', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843189', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843139', 'drugName': 'Baricitinib', 'tradeNames_list': "['Olumiant']", 'syns_list': "['Baricitinib', 'Baricitinib phosphate', 'Baricitinib phosphate saltINCB-028050', 'INCB028050', 'Incb-28050', 'LY-3009104', 'LY3009104']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.505 | Q34 | What are the names of the genes that are targeted by the drug Doxepin Hydrochloride in the treatment of atopic eczema? | In the context of atopic eczema, the drug Doxepin Hydrochloride targets the gene solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%doxepin hydrochloride%" OR LOWER(tradeNames_list) LIKE "%doxepin hydrochloride%" OR LOWER(syns_list) LIKE "%doxepin hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440813', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440837', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440845', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440853', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440869', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440877', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440885', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440901', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440909', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440917', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440925', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440941', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440949', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440957', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440965', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440973', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440981', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440989', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440997', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441005', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440893', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440829', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440797', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440781', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440773', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440933', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440861', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440821', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440805', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440789', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.744 | Q34 | What are the names of the genes that are targeted by the drug Buprenorphine in the treatment of pain? | In the context of pain, the drug Buprenorphine targets the gene opioid receptor mu 1 and opioid receptor kappa 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%buprenorphine%" OR LOWER(tradeNames_list) LIKE "%buprenorphine%" OR LOWER(syns_list) LIKE "%buprenorphine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764755', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764363', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764641', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764137', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764055', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764867', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764307', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764193', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764531', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764389', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764642', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764445', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764249', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764811', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764083', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764277', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764279', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764893', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764166', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764894', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764895', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764335', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764503', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764194', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764559', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764111', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764391', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764697', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764222', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764643', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764054', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764699', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764447', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764725', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764250', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764865', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764139', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764810', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764809', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764839', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764278', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764838', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764837', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764949', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764866', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764305', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764306', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764923', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764167', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764922', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764921', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764334', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764501', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764053', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764529', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764110', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764361', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764614', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764195', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764558', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764557', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764613', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764390', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764587', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764586', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764753', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764081', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764417', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764418', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764671', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764223', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764670', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764669', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764727', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764446', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764698', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764082', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764726', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764138', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764473', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764474', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764950', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764251', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764782', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764781', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764977', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764951', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764754', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764615', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764530', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764502', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764333', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764109', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764362', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764585', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764419', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764783', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764165', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764221', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764475', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1833 | Q34 | What are the names of the genes that are targeted by the drug Pegcetacoplan in the treatment of immune system disease? | In the context of immune system disease, the drug Pegcetacoplan targets the gene complement C3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%pegcetacoplan%" OR LOWER(tradeNames_list) LIKE "%pegcetacoplan%" OR LOWER(syns_list) LIKE "%pegcetacoplan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103147', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103165', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103171', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103177', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103135', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103123', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103117', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103159', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103153', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103141', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}, {'UUID': 'DrugTargetsIndication121923_text_1103129', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'syns_list': "['APL-2', 'Pegcetacoplan']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'C3', 'approvedName': 'complement C3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.874 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac Sodium in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Diclofenac Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%diclofenac sodium%" OR LOWER(tradeNames_list) LIKE "%diclofenac sodium%" OR LOWER(syns_list) LIKE "%diclofenac sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_836126', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836180', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836198', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836216', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836252', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836270', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836288', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836324', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836342', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836360', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836378', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836414', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836432', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836450', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836468', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836486', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836504', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836522', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836540', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836558', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836576', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836612', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836630', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836648', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836666', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836684', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836720', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836738', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836756', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836774', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836792', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836810', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836828', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836846', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836864', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836882', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836900', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836918', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836936', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836954', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836594', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836306', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836162', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836090', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836054', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836036', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836702', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836396', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836234', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836144', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836108', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836072', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.736 | Q34 | What are the names of the genes that are targeted by the drug Naldemedine Tosylate in the treatment of Constipation? | In the context of Constipation, the drug Naldemedine Tosylate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%constipation%" OR LOWER(efo_term) LIKE "%constipation%") AND (LOWER(drugName) LIKE "%naldemedine tosylate%" OR LOWER(tradeNames_list) LIKE "%naldemedine tosylate%" OR LOWER(syns_list) LIKE "%naldemedine tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763382', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763385', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763379', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763376', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763374', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763383', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763380', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763377', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.543 | Q34 | What are the names of the genes that are targeted by the drug Azelastine Hydrochloride in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Azelastine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%azelastine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%azelastine hydrochloride%" OR LOWER(syns_list) LIKE "%azelastine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455911', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455935', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455943', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455951', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455895', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455879', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455871', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455927', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455919', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455903', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455887', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1210 | Q34 | What are the names of the genes that are targeted by the drug Propranolol Hydrochloride in the treatment of stroke? | In the context of stroke, the drug Propranolol Hydrochloride targets the gene adrenoceptor beta 2 and adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%propranolol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%propranolol hydrochloride%" OR LOWER(syns_list) LIKE "%propranolol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937041', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937018', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937087', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937064', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.702 | Q34 | What are the names of the genes that are targeted by the drug Betrixaban in the treatment of venous thromboembolism? | In the context of venous thromboembolism, the drug Betrixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%venous thromboembolism%" OR LOWER(efo_term) LIKE "%venous thromboembolism%") AND (LOWER(drugName) LIKE "%betrixaban%" OR LOWER(tradeNames_list) LIKE "%betrixaban%" OR LOWER(syns_list) LIKE "%betrixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710819', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710843', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710851', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710859', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710835', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710803', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710787', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710779', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710867', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710827', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710811', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710795', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1377 | Q34 | What are the names of the genes that are targeted by the drug Guanfacine Hydrochloride in the treatment of hypertension? | In the context of hypertension, the drug Guanfacine Hydrochloride targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%guanfacine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%guanfacine hydrochloride%" OR LOWER(syns_list) LIKE "%guanfacine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025306', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025312', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025314', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025316', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025320', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025322', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025324', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025328', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025330', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025332', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025334', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025338', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025340', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025342', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025326', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025310', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025302', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025298', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025296', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025336', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025318', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025308', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025304', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025300', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1361 | Q34 | What are the names of the genes that are targeted by the drug Ibrutinib in the treatment of chronic lymphocytic leukemia? | In the context of chronic lymphocytic leukemia, the drug Ibrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic lymphocytic leukemia%" OR LOWER(efo_term) LIKE "%chronic lymphocytic leukemia%") AND (LOWER(drugName) LIKE "%ibrutinib%" OR LOWER(tradeNames_list) LIKE "%ibrutinib%" OR LOWER(syns_list) LIKE "%ibrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_995262', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995400', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995446', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995492', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995584', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995630', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995676', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995768', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995814', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995860', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995906', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995998', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996044', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996090', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996136', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996182', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996228', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996274', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996320', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996366', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996412', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996504', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996550', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996596', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996642', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996688', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996780', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996826', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996872', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996918', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996964', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997010', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997056', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997102', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997148', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997194', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997240', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997286', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997332', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997378', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997424', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997470', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997516', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997562', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997608', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997654', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997700', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997746', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997792', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997838', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997884', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997976', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998022', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998068', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998114', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998160', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998206', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998298', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998344', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998390', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998436', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998482', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998528', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998574', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998620', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998666', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998712', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998758', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998804', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998850', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998896', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998942', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998988', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999034', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999080', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999126', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999172', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999218', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999264', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999310', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999356', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999402', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999448', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999494', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999540', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999586', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997930', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996458', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995722', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995354', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995170', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995078', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995032', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998252', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996734', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995952', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995538', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995308', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995216', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995124', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1153 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of mouth neoplasm? | Trametinib has not been approved by the FDA as a treatment for mouth neoplasm, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mouth neoplasm%" OR LOWER(efo_term) LIKE "%mouth neoplasm%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928701', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928821', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928861', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928901', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928981', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929021', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929061', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929141', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929181', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929221', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929261', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929341', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929381', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929421', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929461', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929501', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929541', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929581', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929621', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929661', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929701', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929781', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929821', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929861', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929901', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929941', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930021', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930061', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930101', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930141', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930181', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930221', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930261', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930301', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930341', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930381', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930421', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930461', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930501', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930541', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930581', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930621', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930661', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930701', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930741', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930781', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930821', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930861', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930901', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930941', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930981', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931061', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931101', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931141', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931181', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931221', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931261', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931341', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931381', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931421', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931461', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931501', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931541', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931581', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931621', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931661', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931701', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931741', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931781', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931821', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931861', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931901', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931941', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931981', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932021', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932061', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932101', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932141', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932181', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932221', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932261', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932301', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932341', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932381', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932421', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932461', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931021', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929741', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929101', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928781', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928621', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928541', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928501', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931301', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929981', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929301', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928941', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928741', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928661', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928581', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'mouth neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1038 | Q34 | What are the names of the genes that are targeted by the drug Duvelisib in the treatment of follicular lymphoma? | In the context of follicular lymphoma, the drug Duvelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%follicular lymphoma%" OR LOWER(efo_term) LIKE "%follicular lymphoma%") AND (LOWER(drugName) LIKE "%duvelisib%" OR LOWER(tradeNames_list) LIKE "%duvelisib%" OR LOWER(syns_list) LIKE "%duvelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858840', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858900', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858920', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858940', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858980', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859000', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859020', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859060', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859080', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859100', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859120', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859160', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859180', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859200', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859220', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859240', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859260', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859280', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859040', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858880', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858800', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858760', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858740', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859140', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858960', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858860', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858820', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858780', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.374 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of ulcerative colitis? | In the context of ulcerative colitis, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ulcerative colitis%" OR LOWER(efo_term) LIKE "%ulcerative colitis%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218675', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219299', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219507', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219715', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220131', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220339', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220547', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240813', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240895', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240977', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241059', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241223', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241305', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241387', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241469', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241551', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241633', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241715', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241797', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241879', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220755', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219091', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218259', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217843', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217635', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241141', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219923', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218883', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218467', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218051', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.672 | Q34 | What are the names of the genes that are targeted by the drug Apremilast in the treatment of psoriasis? | In the context of psoriasis, the drug Apremilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%apremilast%" OR LOWER(tradeNames_list) LIKE "%apremilast%" OR LOWER(syns_list) LIKE "%apremilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696851', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696905', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696907', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696933', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696961', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696963', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696989', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697017', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697019', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697045', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697047', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697075', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697101', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697103', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697129', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697131', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697157', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697159', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697185', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697187', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697213', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697241', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697243', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697269', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697271', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697297', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697325', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697327', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697353', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697355', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697381', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697383', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697409', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697411', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697437', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697439', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697465', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697467', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697493', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697495', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697521', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697523', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697549', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697551', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697577', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697579', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697605', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697607', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697633', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697635', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697661', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697689', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697691', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697717', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697719', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697745', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697747', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697775', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697801', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697803', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697829', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697831', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697857', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697859', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697885', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697887', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697913', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697915', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697941', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697943', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697969', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697971', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697997', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697999', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698025', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698027', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698053', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698055', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698081', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698083', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698109', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698111', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698137', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698139', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698165', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698167', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697663', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697215', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696991', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696879', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696823', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696795', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696793', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697773', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697299', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697073', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696935', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696877', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696849', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696821', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1937 | Q34 | What are the names of the genes that are targeted by the drug Belzutifan in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Belzutifan targets the gene endothelial PAS domain protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%belzutifan%" OR LOWER(tradeNames_list) LIKE "%belzutifan%" OR LOWER(syns_list) LIKE "%belzutifan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192112', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192120', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.359 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232529', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232610', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232637', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232664', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232718', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232745', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232772', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232826', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232853', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232880', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232907', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232961', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232988', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233015', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233042', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233069', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233096', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233123', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233150', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233177', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233204', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233258', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233285', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233312', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233339', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233366', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233420', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233447', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233474', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233501', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233528', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233555', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233582', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233609', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233636', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233663', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233690', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233717', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233744', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233771', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233798', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233825', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233852', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233879', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233906', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233933', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233960', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233987', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234014', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234041', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234068', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234122', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234149', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234176', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234203', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234230', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234257', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234311', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234338', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234365', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234392', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234419', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234446', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234473', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234500', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234527', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234554', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234581', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234608', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234635', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234662', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234689', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234716', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234743', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234770', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234797', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234824', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234851', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234878', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234905', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234932', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234959', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234986', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235013', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235040', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235067', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234095', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233231', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232799', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232583', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232475', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232421', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232394', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234284', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233393', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232934', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232691', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232556', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232502', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232448', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.974 | Q34 | What are the names of the genes that are targeted by the drug Abrocitinib in the treatment of atopic eczema? | In the context of atopic eczema, the drug Abrocitinib targets the gene Janus kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%abrocitinib%" OR LOWER(tradeNames_list) LIKE "%abrocitinib%" OR LOWER(syns_list) LIKE "%abrocitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848713', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848731', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848725', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848701', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848683', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848689', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848719', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848707', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848695', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.789 | Q34 | What are the names of the genes that are targeted by the drug Olaparib in the treatment of ovarian neoplasm? | In the context of ovarian neoplasm, the drug Olaparib targets the gene poly(ADP-ribose) polymerase 2, poly(ADP-ribose) polymerase 1 and poly(ADP-ribose) polymerase family member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ovarian neoplasm%" OR LOWER(efo_term) LIKE "%ovarian neoplasm%") AND (LOWER(drugName) LIKE "%olaparib%" OR LOWER(tradeNames_list) LIKE "%olaparib%" OR LOWER(syns_list) LIKE "%olaparib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_795125', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795192', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795257', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795258', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795324', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795325', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795326', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795392', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795393', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795458', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795459', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795525', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795526', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795527', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795592', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795593', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795594', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795659', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795660', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795661', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795726', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795728', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795793', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795794', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795795', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795860', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795862', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795927', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795928', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795929', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795994', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795995', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795996', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796061', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796062', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796063', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796128', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796129', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796130', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796195', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796196', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796197', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796262', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796263', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796264', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796329', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796330', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796331', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796396', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796397', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796398', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796464', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796465', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796530', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796531', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796532', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796597', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796599', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796664', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796665', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796666', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796731', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796732', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796733', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796798', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796799', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796800', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796865', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796866', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796867', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796932', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796933', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796934', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796999', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797000', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797001', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797066', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797067', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797068', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797133', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797134', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797135', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797200', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797201', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797202', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797267', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796463', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795727', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795391', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795191', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795123', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795057', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795056', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796598', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795861', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795460', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795259', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795190', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795124', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795058', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.740 | Q34 | What are the names of the genes that are targeted by the drug Morphine Sulfate in the treatment of cancer? | In the context of cancer, the drug Morphine Sulfate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%morphine sulfate%" OR LOWER(tradeNames_list) LIKE "%morphine sulfate%" OR LOWER(syns_list) LIKE "%morphine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763496', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763553', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763572', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763591', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763629', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763648', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763667', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763705', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763724', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763743', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763762', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763800', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763819', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763838', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763857', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763876', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763895', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763914', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763933', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763952', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763971', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764009', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764028', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763990', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763686', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763534', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763420', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763401', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763458', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763781', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763610', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763515', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763477', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763439', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1042 | Q34 | What are the names of the genes that are targeted by the drug Ziconotide in the treatment of pain? | In the context of pain, the drug Ziconotide targets the gene calcium voltage-gated channel subunit alpha1 B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%ziconotide%" OR LOWER(tradeNames_list) LIKE "%ziconotide%" OR LOWER(syns_list) LIKE "%ziconotide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_891741', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891747', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891749', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891751', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891755', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891757', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891759', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891763', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891765', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891767', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891769', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914653', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914655', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914657', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914659', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914661', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914663', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914665', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914667', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914669', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914671', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914675', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914677', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914679', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914681', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914683', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914687', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914689', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914673', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891761', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891745', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891737', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891733', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891731', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914685', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914651', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891753', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891743', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891739', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891735', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.977 | Q34 | What are the names of the genes that are targeted by the drug Ribociclib Succinate in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Ribociclib Succinate targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%ribociclib succinate%" OR LOWER(tradeNames_list) LIKE "%ribociclib succinate%" OR LOWER(syns_list) LIKE "%ribociclib succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848943', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848952', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848955', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848958', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848964', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848967', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848970', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848976', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848979', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848982', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848985', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848991', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848994', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848997', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849000', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849003', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849006', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849009', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849012', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849015', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849018', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849024', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849027', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849030', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849033', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849036', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849042', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849045', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849021', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848973', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848949', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848937', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848931', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848928', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849039', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848988', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848961', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848946', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848940', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848934', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1511 | Q34 | What are the names of the genes that are targeted by the drug Vismodegib in the treatment of skin basal cell carcinoma? | In the context of skin basal cell carcinoma, the drug Vismodegib targets the gene smoothened, frizzled class receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin basal cell carcinoma%" OR LOWER(efo_term) LIKE "%skin basal cell carcinoma%") AND (LOWER(drugName) LIKE "%vismodegib%" OR LOWER(tradeNames_list) LIKE "%vismodegib%" OR LOWER(syns_list) LIKE "%vismodegib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072560', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072585', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072610', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1473 | Q34 | What are the names of the genes that are targeted by the drug Avatrombopag Maleate in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Avatrombopag Maleate targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%avatrombopag maleate%" OR LOWER(tradeNames_list) LIKE "%avatrombopag maleate%" OR LOWER(syns_list) LIKE "%avatrombopag maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055940', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055938', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055944', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055942', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1510 | Q34 | What are the names of the genes that are targeted by the drug Vismodegib in the treatment of basal cell carcinoma? | In the context of basal cell carcinoma, the drug Vismodegib targets the gene smoothened, frizzled class receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%basal cell carcinoma%" OR LOWER(efo_term) LIKE "%basal cell carcinoma%") AND (LOWER(drugName) LIKE "%vismodegib%" OR LOWER(tradeNames_list) LIKE "%vismodegib%" OR LOWER(syns_list) LIKE "%vismodegib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072585', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072609', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072559', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072610', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072584', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072560', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072553', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Basal Cell Nevus Syndrome', 'efo_term': 'nevoid basal cell carcinoma syndrome', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072578', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Basal Cell Nevus Syndrome', 'efo_term': 'nevoid basal cell carcinoma syndrome', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1072603', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'syns_list': "['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Basal Cell Nevus Syndrome', 'efo_term': 'nevoid basal cell carcinoma syndrome', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1477 | Q34 | What are the names of the genes that are targeted by the drug Eltrombopag Olamine in the treatment of severe aplastic anemia? | In the context of severe aplastic anemia, the drug Eltrombopag Olamine targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%severe aplastic anemia%" OR LOWER(efo_term) LIKE "%severe aplastic anemia%") AND (LOWER(drugName) LIKE "%eltrombopag olamine%" OR LOWER(tradeNames_list) LIKE "%eltrombopag olamine%" OR LOWER(syns_list) LIKE "%eltrombopag olamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055974', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055989', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055994', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055999', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056009', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056014', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056019', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056029', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056034', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056039', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056044', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056054', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056059', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056064', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056069', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056074', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056079', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056084', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056089', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056094', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056099', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056109', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056114', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056119', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056124', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056129', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056139', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056144', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056149', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056154', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056159', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056164', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056169', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056174', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056179', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056184', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056189', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056194', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056199', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056204', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056209', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056214', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056219', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056224', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056229', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056234', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056239', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056244', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056249', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056254', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056259', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056269', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056274', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056279', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056284', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056289', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056294', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056304', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056309', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056314', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056319', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056324', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056329', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056334', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056339', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056344', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056349', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056354', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056359', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056364', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056369', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056374', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056379', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056384', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056389', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056394', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056399', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056404', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056409', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056414', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056419', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056424', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056429', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056434', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056439', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056444', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056264', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056104', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056024', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055984', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055964', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055954', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055949', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056299', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056134', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056049', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056004', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055979', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055969', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055959', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.